Mandy Ma1, Heather R Adams2, Laurie E Seltzer3, William B Dobyns4, Alex R Paciorkowski5. 1. University of Buffalo School of Medicine, Buffalo, NY. 2. Department of Neurology, University of Rochester Medical Center, Rochester, NY. 3. Department of Neurology, University of Rochester Medical Center, Rochester, NY; Strong Epilepsy Center, University of Rochester Medical Center, Rochester, NY. 4. Department of Neurology, University of Washington, Seattle, WA; Division of Medical Genetics, Department of Pediatrics, University of Washington, Seattle, WA; Center for Integrative Brain Research, Seattle Children's Research Institute, Seattle, WA. 5. Department of Neurology, University of Rochester Medical Center, Rochester, NY; Departments of Pediatrics and Biomedical Genetics, University of Rochester Medical Center, Rochester, NY; Center for Neural Development and Disease, University of Rochester Medical Center, Rochester, NY. Electronic address: Alex_Paciorkowski@urmc.rochester.edu.
Abstract
OBJECTIVE: To differentiate developmental encephalopathies by creating a novel quantitative phenotyping tool. STUDY DESIGN: We created the Developmental Encephalopathy Inventory (DEI) to differentiate disorders with complex multisystem neurodevelopmental symptoms. We then used the DEI to study the phenotype features of 20 subjects with FOXG1 disorder and 11 subjects with MECP2 disorder. RESULTS: The DEI identified core domains of fine motor and expressive language that were severely impaired in both disorders. Individuals with FOXG1 disorder were overall more severely impaired. Subjects with FOXG1 disorder were less able to walk, had worse fine motor skills, more disability in receptive language and reciprocity, and had more disordered sleep than did subjects with MECP2 disorder (P <.05). Covariance, cluster, and principal component analysis confirmed a relationship between impaired awareness, reciprocity, and language in both disorders. In addition, abnormal ambulation was a first principal component for FOXG1 but not for MECP2 disorder, suggesting that impaired ambulation is a strong differentiating factor clinically between the 2 disorders. CONCLUSIONS: We have developed a novel quantitative developmental assessment tool for developmental encephalopathies and propose this tool as a method to identify and illustrate core common and differential domains of disability in these complex disorders. These findings demonstrate clear phenotype differences between FOXG1 and MECP2 disorders.
OBJECTIVE: To differentiate developmental encephalopathies by creating a novel quantitative phenotyping tool. STUDY DESIGN: We created the Developmental Encephalopathy Inventory (DEI) to differentiate disorders with complex multisystem neurodevelopmental symptoms. We then used the DEI to study the phenotype features of 20 subjects with FOXG1 disorder and 11 subjects with MECP2 disorder. RESULTS: The DEI identified core domains of fine motor and expressive language that were severely impaired in both disorders. Individuals with FOXG1 disorder were overall more severely impaired. Subjects with FOXG1 disorder were less able to walk, had worse fine motor skills, more disability in receptive language and reciprocity, and had more disordered sleep than did subjects with MECP2 disorder (P <.05). Covariance, cluster, and principal component analysis confirmed a relationship between impaired awareness, reciprocity, and language in both disorders. In addition, abnormal ambulation was a first principal component for FOXG1 but not for MECP2 disorder, suggesting that impaired ambulation is a strong differentiating factor clinically between the 2 disorders. CONCLUSIONS: We have developed a novel quantitative developmental assessment tool for developmental encephalopathies and propose this tool as a method to identify and illustrate core common and differential domains of disability in these complex disorders. These findings demonstrate clear phenotype differences between FOXG1 and MECP2 disorders.
Authors: Debra E Weese-Mayer; Steven P Lieske; Christina M Boothby; Anna S Kenny; Heather L Bennett; Jean M Silvestri; Jan-Marino Ramirez Journal: Pediatr Res Date: 2006-08-28 Impact factor: 3.756
Authors: Martin Krzywinski; Jacqueline Schein; Inanç Birol; Joseph Connors; Randy Gascoyne; Doug Horsman; Steven J Jones; Marco A Marra Journal: Genome Res Date: 2009-06-18 Impact factor: 9.043
Authors: Apostolos Papandreou; Ruth B Schneider; Erika F Augustine; Joanne Ng; Kshitij Mankad; Esther Meyer; Amy McTague; Adeline Ngoh; Cheryl Hemingway; Robert Robinson; Sophia M Varadkar; Maria Kinali; Vincenzo Salpietro; Margaret C O'Driscoll; S Nigel Basheer; Richard I Webster; Shekeeb S Mohammad; Shpresa Pula; Marian McGowan; Natalie Trump; Lucy Jenkins; Frances Elmslie; Richard H Scott; Jane A Hurst; Belen Perez-Duenas; Alexander R Paciorkowski; Manju A Kurian Journal: Neurology Date: 2016-03-30 Impact factor: 9.910
Authors: Scott Demarest; Elia M Pestana-Knight; Heather E Olson; Jenny Downs; Eric D Marsh; Walter E Kaufmann; Carol-Anne Partridge; Helen Leonard; Femida Gwadry-Sridhar; Katheryn Elibri Frame; J Helen Cross; Richard F M Chin; Sumit Parikh; Axel Panzer; Judith Weisenberg; Karen Utley; Amanda Jaksha; Sam Amin; Omar Khwaja; Orrin Devinsky; Jeffery L Neul; Alan K Percy; Tim A Benke Journal: Pediatr Neurol Date: 2019-03-27 Impact factor: 3.372
Authors: Jacinta Saldaris; Judith Weisenberg; Elia Pestana-Knight; Eric D Marsh; Bernhard Suter; Rajsekar Rajaraman; Gena Heidary; Heather E Olson; Orrin Devinsky; Dana Price; Peter Jacoby; Helen Leonard; Tim A Benke; Scott Demarest; Jenny Downs Journal: J Child Neurol Date: 2021-08-11 Impact factor: 1.987
Authors: Elaine M Morazzani; Jaimee R Compton; Dagmar H Leary; Angela V Berry; Xin Hu; Juan J Marugan; Pamela J Glass; Patricia M Legler Journal: Antiviral Res Date: 2019-02-10 Impact factor: 10.103
Authors: Cary Fu; Dallas Armstrong; Eric Marsh; David Lieberman; Kathleen Motil; Rochelle Witt; Shannon Standridge; Paige Nues; Jane Lane; Tristen Dinkel; Monica Coenraads; Jana von Hehn; Mary Jones; Katie Hale; Bernhard Suter; Daniel Glaze; Jeffrey Neul; Alan Percy; Timothy Benke Journal: BMJ Paediatr Open Date: 2020-09-13
Authors: Tellen D Bennett; Tiffany J Callahan; James A Feinstein; Debashis Ghosh; Saquib A Lakhani; Michael C Spaeder; Stanley J Szefler; Michael G Kahn Journal: J Pediatr Date: 2019-01-25 Impact factor: 4.406